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Summary Four patients with chronic lymphocytic leukaemia were treated by one or more infusions of
polyclonal antibody specific for the immunoglobulin idiotype expressed on their leukaemic cells. The antibody
was in the form of IgG from sheep antiserum.
Three of the 4 cases showed a significant fall in blood lymphocyte count. On one occasion most of the
residual circulating lymphocytes were apparently dead. However on all occasions the cell counts rebounded to
near pre-infusion levels within one week.
Viable lymphocytes recovered from the blood after infusion always showed evidence of antigenic
modulation: a diminished level of surface idiotype in a patched distribution, with an accompanying
refractoriness to lysis by anti-idiotype plus complement.
When cultured in vitro blood lymphocytes from three of the four patients revealed an appreciable export of
idiotypic Ig. These 3 patients showed plasma levels of idiotypic Ig up to 400pgml-1, reduced by plasma
exchange prior to infusion. The fourth patient had a level of less than 4 iugml-1, and was the only one in
whom free antibody could be found in the plasma after infusion.
These cases demonstrate two major factors which thwart antibody attack on leukaemic cells - extracellular
antigen and antigenic modulation - as well as problems relating to sparseness of surface antigen, recruitment
ofeffectors, and exhaustion ofeffectors.
Surface immunoglobulin (Ig) on neoplastic B
lymphocytes is idiotypically homogeneous for each
individual tumour, both in those tumours which
exhibit an obvious monoclonal plasma Ig (Wernet
et al., 1972) and those which do not (Stevenson &
Stevenson, 1975; Hough et al., 1976). The latter
group offer a promising therapeutic target for
antibody reacting with their idiotypic determinants
(anti-idiotype).
Polyclonal anti-idiotype has been used to treat
both animal (G.T. Stevenson et al., 1977; Haughton
et al., 1978; Krolick et al., 1979) and human
(Hamblin et al., 1980) B-cell leukaemias, with only
modest success. In contrast a case of human
follicular lymphoma treated with monoclonal anti-
idiotype underwent dramatic regression, despite the
antibody not being cytotoxic to cells in vitro (Miller
et al., 1982). It may be that the tumour described
by Miller et al. exhibited physiological suppression
by anti-idiotype, analogous to what has been
described in normal lymphoid populations
(Nisonoff & Bangasser, 1975), whereas the other
treated tumours were simply subjected to cytotoxic
attack by antibody (Stevenson & Stevenson, 1975).
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Such a dichotomy could reflect the fact that
follicular lymphoma is sometimes responsive to
physiological signals (Jaffe, 1982). Alternatively the
different results could reflect differences between
monoclonal and polyclonal anti-idiotype, antibody
dose, or other factors: the question could be
resolved by further therapeutic experience. The
therapeutic use of monoclonal antibodies against
non-Ig lymphoma antigens (reviewed by Ritz &
Schlossman, 1982) has revealed barriers similar to
those encountered by polyclonal anti-idiotype in the
present studies.
Here we describe further experience in treating
human chronic lymphocytic leukaemia (CLL) with
polyclonal anti-idiotype. Leukaemic cells, at least
when in the bloodstream, are likely to be
susceptible to killing by antibody and complement
in a manner analogous to what can be observed in
vitro, and our experience focusses attention on
some of the important ways whereby the cells can
elude such destruction.
Patients
1. C.W., a white male aged 73, was diagnosed in
May 1978 as having CLL with features character-
istic of the prolymphocytic variant (Galton et al.,
1974). On presentation there was an enlarged left
axillary node, splenomegaly 6cm below the costal
margin, and a white cell count 92 x 1091-1 with
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99% lymphocytes. Over the next 5 months the
white cell count doubled and haemoglobin and
platelet levels fell. From December 1978
progression was retarded by leukaphereses up to
fortnightly in frequency. In October and November
1979, when the white cell count was 256 x109I1,
infusions of polyclonal anti-idiotype each appeared
to remove some 10% of the total tumour load
(Hamblin et al., 1980). Subsequently he was treated
by chemotherapy (chlorambucil 10mgday-1 and
prednisolone 20mg day-1) and, somewhat
surprisingly in view of the prolymphocytic nature
of his tumour, responded well. However, the
remission could not be maintained and in February
1981, having had no chemotherapy for 3 months,
he was given his third course of anti-idiotype. Prior
to this his white cell count was 12 x 1091-1, haemo-
globin 16gdl-1, platelets IlOx 1091-1; the spleen
was palpable 4cm below the coastal margin.
As described previously (Hamblin et al., 1980)
this patient's cells were larger and more blastic than
is usual in CLL, these being features of the pro-
lymphocytic variant. The cell surfaces exhibited
IgM and IgD of light chain class A, together with
FcA and C3 receptors.
2. O.J., a white male, presented in November 1972
at the age of 76 with markedly enlarged lymph
nodes in cervical, axillary and inguinal regions. The
spleen and liver were not palpable. Herpes zoster
was present over the right T2 area. The white cell
count was 97 x 1091- with 96% lymphocytes,
haemoglobin 13.9gdl -1, platelets 147 x 1091-1.
Serum Ig levels were normal. He was not given any
specific treatment. Twelve months later the white
cell count had reached 161 x 1091-1, and a
remission was induced by chlorambucil. A second
course of chlorambucil was needed in May 1975
but the drug had to be stopped because of a severe
flare-up of facial herpes simplex. It was
subsequently noted that both chlorambucil and
prednisolone tended to reactivate the herpes
simplex to a distressing extent. From May 1978 the
disease was imperfectly controlled by leukaphereses
at a frequency up to fortnightly. In January 1980,
immediately prior to antibody infusion, there was
widespread and pronounced peripheral lympha-
denopathy, a spleen palpable 2cm below the costal
margin, white cell count 296 x1091-1 with >99%
lymphocytes, haemoglobin 10.3gdl-1, and platelet
count 66 x 109 -1.
The leukaemic cells displayed surface Ig and Fcy
receptor, with no C3 receptor. More than 60% of
the cells were positive for u, 6, y and K chains by
both immunofluorescence and erythrocyte-rosetting.
However, the surface IgG thereby revealed was
idiotype-negative (Stevenson et al., 1981). leading to
the conclusion that the intrinsic surface Ig was
IgMK plus IgDKc.
3. M.W., a white female, presented in September
1977 at the age of 71 complaining of lassitude.
There was bilateral lymphadenopathy in cervical,
axillary and inguinal regions and the spleen was
enlarged to 12cm below the costal margin. The
white cell count was 419 x 1091-1, 99% lympho-
cytes characteristic of CLL, haemoglobin 8.1 gdl 1,
platelets 165 x 1091-1. She was treated with
chlorambucil 5mg/day and prednisolone
10mgday-1 for one month, abolishing all physical
signs of the disease and restoring the blood counts
to near normal. Subsequently her white cell count
was seen to double about every 6 weeks and the
disease was controlled with intermittent chloram-
bucil and prednisolone. However in November 1978
she developed a severe attack of herpes zoster in
the left T7 distribution: this has never properly
healed and has been worsened by attempts to
control her CLL with cytotoxic drugs. The infusion
of anti-idiotype described in this report was carried
out in July 1980, with the white cell count at
112x 109P1- (lymphocytes 97%), haemoglobin
10.0gdI -1, platelets 155 x 1091 -1.
The leukaemic cells showed surface IgM and IgD
of light chain class A, together with Fcy and C3
receptors. They formed rosettes with mouse
erythrocytes.
4. D.H., a white male, presented in July 1974 at the
age of 53 complaining of lassitude. There were no
physical signs but his white cell count was
18.2x 1091-1, with lymphocytes 66% and a film
characteristic of CLL. The disease appeared only
slowly progressive, the white cell count taking 2
years to double, and no treatment was given. In
March 1981, immediately before his infusion with
anti-idiotype, his white cell count was 53.9 x 1091-1
(lymphocytes 90%), haemoglobin 13.4gdl-1,
platelets 113 x 1091-1.
The leukaemic cells showed surface IgMK, with
smaller amounts of IgD and IgG; again the latter
proved not to be idiotype-positive. Both Fcy and
C3 receptors were present.
Materials and methods
Leukaphereses and plasma exchanges were carried
out using a Haemonetics 30 discontinuous cell
separator.
For each patient FabM was prepared from the
surface IgM of a blood lymphocyte sample
(between 1010 and 4 x 1010 cells) obtained by leuka-
pheresis. This fragment was used as immunogen for
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methods are described in detail elsewhere
(Stevenson et al., 1983). The IgG1 subclass was
separated from the serum with a yield of about
15mgml-1, as described previously (Hamblin et al.,
1980). Antibody activity against the constant
regions of the Fabp was removed by passing it
through an immunosorbent column containing
immobilized human IgM. The IgG1 was then
confirmed, by indirect immunofluorescence, to
contain antibody reacting with the surface Ig of the
homologous CLL cells, but not with other CLL
cells nor with normal lymphocytes. Immediately
prior to infusion all aggregate was removed from
the IgG1 by passing it through a column of
Sephacryl S300 (Pharmacia) equilibrated with sterile
physiological saline. The monodisperse Ig emerging
from the column passed through a 0.22pm filter
(Millipore), and was required to pass the limulus
amoebocyte test for pyrogens (Pyrogent test,
Mallinckrodt).
Three days before each antibody infusion the
patient started a course of allopurinol, 300mg
daily, to prevent hyperuricaemia. As soon as the
preparation for infusion became available it was
used in a cutaneous prick test for immediate hyper-
sensitivity. Any patient who had received a
previous infusion of sheep antibody also had his
serum examined for precipitins to sheep IgG1, by a
micro-Ouchterlony technique capable of detecting
5-10pgml-1 of antibody. Infusion was carried out
slowly by the intravenous route, as described
individually for each patient, with careful
monitoring ofpulse, respiration and temperature.
The secretion of IgG by CLL cells maintained in
short-term culture was studied as described
previously (Stevenson et al., 1980). Ig levels in
culture supernatants and patients' sera were
assessed by solid phase radioimmunoassay (Eady et
al., 1975).
In assessing the content of idiotypic Ig in
patients' sera the radioimmunoassay utilized anti-
idiotype IgG bound to Sephadex G-25 superfine
(Pharmacia) as solid phase, and idiotypic penta-
meric IgM as standard and radioiodinated antigen.
This IgM had been prepared by sequential
immunosuppression of the patient's serum: first to
separate total IgM, then the idiotypic IgM
(Stevenson et al., 1980). Iodination was by the
lodo-gen method (Pierce Chemical Co.). The assay
is sensitive to any class of serum Ig which exhibits
the tumour idiotype, with the major contributions
expected from IgM and IgD exported by the
tumour.
Determinations of cell lysis by antibody and
complement were carried out as described by F.K.
Stevenson et al. (1977). Percentages of specific 5'Cr-
release were taken as:
(counts released by antibody - counts released by
normal IgG)/(counts released by detergent - counts
released by normal IgG) x 100
where detergent lysis was carried out in Nonidet
P40.
Results
Studies before treatment
Visual assessment by direct immunofluorescence
revealed CW cells to have a density of surface Ig
comparable with that on normal peripheral B
lymphocytes, while the Ig on DH, OJ and MW
cells was notably more sparse.
Separated IgG1 and IgG2 fractions of the sheep
anti-idiotype preparations were each tested for their
capacity to invoke complement-mediated cytoxicity
against the appropriate tumour cells. No killing was
observed with any of the IgG2 fractions in
combination with either rabbit or human
complement. In contrast, all the IgG1 preparations
were capable of invoking at least partial killing with
rabbit complement. Killing was specific inasmuch
as anti-idiotype raised against one patient's surface
Ig failed to yield any killing with cells from other
patients. Levels of killing invoked by the IgG1 anti-
idiotypes are shown in Figure 1, and are seen to be
highest for CW cells. In all cases similar or slightly
lower levels of killing were achieved using affinity-
purified IgG antibody directed against the constant
regions of the appropriate light chains.
Using human allogeneic, ABO-compatible serum
as the complement source an appreciable level of
killing (65-72% specific 51Cr-release) was achieved
only with CW cells. Specific 5tCr-release reached
only 10% for OJ, and was zero for DH and MW
cells.
As reported previously (Hamblin et al., 1980)
CW serum contained idiotypic IgM, which rendered
this serum a less effective source of complement
than normal serum when lysis of the patient's cells.
was invoked by anti-idiotype, although equally
effective when lysis was invoked by anti-HLA.
Figure 2 shows the effectiveness of plasmapheresis
in reducing the level of inhibitory component in
CW serum.
Attempts to kill DH cells by the antibody-
dependent cellular cytotoxicity (ADCC) mechanism,
using anti-idiotype in the presence of human blood
luekocytes during 18h incubations, were
unsuccessful both with and without the additional
presence of fresh human serum at 25% as a source
ofcomplement.
The ability of leukaemic cells to elude
complement killing by prior exposure to anti-550 J. GORDON et al.
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Figure 1 Lysis of leukaemic cells in vitro by IgG,
from anti-idiotype serum, in the presence of rabbit
complement. Antibody preparations at the indicated
concentrations were incubated for 15min at 0°C with
51Cr-labelled cells, 105ml-P, from patients CW (C),
OJ (A), MW (0) and DH (A). Fresh rabbit serum
(1.5 volumes, 1:3 in MEM, to give a final serum
concentration of 20%) was then added, the
temperature was raised to 37°C, and the release of
I'Cr from the cells was measured at 30min.
idiotype at 37°C (antigenic modulation) was
assessed for patients CW, MW and DH. Rabbit
complement was used because of the good killing it
afforded, but it should be noted that modulation
against xenogenic complement can be considerably
slower than against syngeneic (Gordon et al., 1981).
Full modulation (that is complete resistance to
complement lysis) developed after incubations for
15-30min at 370C (Figure 3). Figure 4 illustrates
modulation of DH cells as a function of antibody
concentration. Modulation against human
complement was assessed only for CW cells: a
range of concentrations of anti-idiotype induced
modulation rapidly (Figure 5). The redistribution of
surface antigen-antibody complexes which underlies
modulation was observed by indirect immuno-
fluorescence. Incubation with anti-idiotype at 37°C
induced endocytosis either via antigen-antibody
patches (CW), or via mixtures of patches and caps
(DH and MW).
Leukaemic cells from all patients except DH
secreted detectable amounts of idiotypic Ig into
culture supernatants (Table I). The IgM appearing
0
500 250 125 63 31 16
Antibody (pg ml-1)
Figure 2 Lysis of CW cells invoked by IgG, from
anti-idiotype serum, using as a source ofcomplement a
20% concentration of serum from: (A), a healthy
human subject; (0) CW before plasmapheresis (K)
CW after plasmapheresis.
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Figure 3 Reduced complement lysis (antigenic
modulation) caused by exposing cells to antibody at
37°C before the addition of rabbit complement. Cells
from CW (0); DH (A) and MW (U) at 105ml-P
were preincubated with antibody (IgG, ex anti-
idiotype serum, 250 gml-') at 37°C for the times
indicated. The cell suspensions were then chilled, and
the addition of complement and establishment and
measurement oflysis proceeded as in Figure 1.
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Figure 4 Antigenic modulation of DH cells as a
function of antibody concentration. Cells at 105ml1
were preincubated with antibody (IgG, ex anti-
idiotype serum at the indicated concentrations) for
30min at 0°C (0) or 37°C (0). The 37°C samples
were then chilled, and addition of complement and
subsequent processing occurred as in Figure 1. Note
that there is some escape from modulation at low
concentrations of antibody when using rabbit
complement.
Table I Ig secreted by CLL cells in culture
Ig, ngml-', appearing in supernatants
ofcells cultured at 2 x 107ml- Ifor 5h
Patient IgM IgD
CW 70 17
OJ 42 0
MW 48 7
in the culture supernatants was pentameric rather
than monomeric, confirming that it arose from an
export pathway rather than by turnover of surface
Ig (Stevenson et al., 1980). In accord with the
behaviour of the tumour cells in culture, Ig bearing
the tumour idiotype was detected in the sera of
patients CW, OJ and MW, with levels at the time
of antibody infusion shown in Table II, while no
idiotypic Ig could be recovered from the serum of
DH.
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Figure 5 Antigenic modulation of CW cells
protecting against lysis by human complement. Cells at
105mP-1 were preincubated with IgG, ex anti-idiotype
serum at 400 (A), 100 (A) or 50 (0) pgml-' at 37°C
for the times indicated. The suspensions were then
chilled, and normal human AB serum was added as a
source of complement. The serum dilutions and
subsequent processing were as described in Figure 1.
Note that there is no escape from modulation at the
lowest concentration of antibody.
Antibody administration and its sequels
Patient CW A previous report (Hamblin et al.,
1980) has described the first two treatments of this
patient with anti-idiotype. The third treatment
consisted of two infusions on successive days. On 3
February 1981 the patient underwent a 41 plasma
exchange, with replacement by 21 of plasma protein
fraction and (to maintain complement levels) 21 of
fresh frozen plasma. He then received 1.5g IgGI
from anti-idiotype serum, in 250ml physiological
saline. The infusion proceeded over 3 hours without
untoward reaction. The next morning, 16h after the
end of the infusion, the first blood sample was
taken for study. A further 11 fresh frozen plasma
was infused and then, 20h after the first, a second
lot of 1.5 g IgG1 in 250ml - again over 3 h without
reaction. Blood samples were taken immediately,
19h and 44h later. Twenty-four hours after the
second antibody infusion a final 11 of fresh frozen
plasma was administered.
Effects on the circulating white cells are
summarized in Figure 6. It can be seen that the
count reached a nadir immediately after the second
infusion, but soon rebounded to exceed the pre-
treatment count. However at these times it was
noted that the percentage of cells recoverable from
Ficoll-Triosil layers had fallen appreciably, and
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Figure 6 White cell counts recorded in patient CW
after antibody infusions: total count (O), and cells
recoverable from Ficoll-Triosil (0).
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when the counts of the recoverable (i.e. viable) cells
were plotted a somewhat different pattern emerged.
The nadir was still reached at the same time but the
fall in count was more dramatic, reaching 7% of
the original, and the return to the pre-infusion level
was gradual without a transient surge above this
level. The results imply that at 23, 42 and 67h after
the first infusion there were large numbers of dead
cells in the circulation, apparently including some
entering from the tissues.
The results in Figure 7 illustrate some
characteristics of the viable cells recovered. Staining
for surface Ig by immunofluorescence revealed a
marked drop in the percentage of cells expressing
detectable levels. In addition the intensity of
staining on positive cells decreased, and the pattern
of staining changed from uniform circumferential to
clusters of fluorescent aggregates. The cells negative
for surface Ig were nearly all of tumour
morphology: few T cells (forming rosettes with
sheep erythrocytes) or non-tumour B cells (staining
for surface K) were detectable. No sheep IgG was
detected on the cell surfaces by staining with
fluorescein-labelled anti-sheep IgG, suggesting that
all complexes formed by sheep antibody had been
endocytosed. Some two days following the second
infusion the tumour cells had recovered their
original staining characteristics for surface idiotypic
Ig.
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Figure 7 Characteristics of viable blood lymphocytes recovered from CW after antibody infusions. (a)
Percentages ofcells yielding positive staining with anti-idiotype by indirect immunofluorescence (0), and with
fluorescein-labelled sheep purified anti-A (0). The higher percentage staining with anti-idiotype at the nadir is
likely simply to reflect the higher sensitivity of the indirect staining technique. (b) Lysis achieved by
incubating cells (10sml-1) with antibody at 00, adding serum to 20% as a source of complement, and
warming to 37°C: anti-idiotype plus rabbit complement (A), anti-A plus rabbit complement (m), anti-idiotype
plus human complement (-).
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The capacity of surviving cells to be killed in
vitro by anti-idiotype in the presence of complement
also reflected the perturbations in expression of
surface idiotype resulting from antibody admini-
stration. Thus after the second infusion virtually all
recoverable cells had become resistant to lysis by
anti-idiotype plus human complement, and there
was minimal susceptibility to anti-idiotype or anti-A
plus rabbit complement (Figure 7b). Return to
previous susceptibility accompanied the
reappearance of strong immunofluorescence for
surface idiotype. That complement lysis which
could be invoked by an anti-HLA serum of broad
specificity remained unaltered throughout the
course of treatment.
The level of serum Ig bearing the tumour
idiotype was lowered 63% by plasmapheresis, and
lowered further by the antibody infusions, but did
not reach zero. Over the ensuing days it rose
progressively, more or less in line with the white
cell count (Figure 8).
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Figure 9 White cell counts (lymphocyte counts in the
case of DH) recorded before and after antibody
infusions in patients OJ, MW and DH. Numbers in
brackets refer to times outside the range of the x-axis:
days before or after therapy began.
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Figure 8 Levels of plasma idiotypic Ig in patient CW,
determined by radioimmunoassay.
Patient OJ The patient received one course of
antibody consisting of two infusions on successive
days. On the first day he underwent a 41 plasma
exchange, with replacement by 21 of plasma protein
fraction and 21 of fresh frozen plasma. He was
then given 1.3 g of antibody-containing IgG, in
510ml saline over a period of 5h. No reaction
occurred. The next morning he was given a further
500ml fresh frozen plasma, and then 1.1g IgG, in
470ml saline over 4.5 h. Again no reaction
occurred.
After the two infusions the white cell count
(Figure 9) fell from 230 to 150 x 1091-1. However it
then rose over a period of 3 days to its former
level. No effect was noticed on tumour masses, and
no observations were made on the nature of the
residual circulating white cells.
The patient felt well throughout the period of
treatment, but two weeks after it finished he
developed a chest infection and shortly afterwards
died of bronchopneumonia. Histological
examination of autopsy material revealed
appearances in lymph nodes and spleen typical of
CLL. The kidneys appeared normal: in particular
there was no evidence of immune-complex
deposition as a result of the antibody infusion.
Patient MW This patient also received one course
of antibody consisting of two infusions on
successive days. On the first day she underwent a
41 plasma exchange, with the plasma being replaced
entirely by fresh frozen plasma. Antibody-
containing IgG, (1.3 g) in 500ml saline was then
infused over 5h. The next day she was given a
further 500ml of fresh frozen plasma, then 1.2g of
antibody-containing IgG, in 500ml saline over 5h.
No significant fall in white cell count was observed
(Figure 9), and in all post-infusion blood samples
the percentage of cells recovered after layering over
Ficoll-Triosil remained high. Even after the two
infusions only a small drop in the level of
553554 J. GORDON et al.
Table II Levels of serum idiotypic Ig
Serum idiotypic Ig, ugmlla
Before After After
Patient plasmapheresis plasmapheresis infusionb
CW 180 67 20
OJ 400 160 43
MW 310 140 110
aBy radioimmunoassay in which the standard antigen
was idiotypic pentameric JgM.
bSerum samples taken within 4h of completing antibody
infusions.
circulating idiotype-positive Ig was observed (Table
II).
Cells processed from a sample taken 4h after the
first infusion were shown by indirect fluorescence
microscopy to be coated with sheep antibody:
about 10% stained strongly for sheep IgG, while a
further 40% exhibited weak to moderate staining.
The sheep antibody, and the intrinsic surface Ig
examined separately, showed spottiness of fluo-
rescence but no gross redistribution. The next day,
immediately before the second infusion, the blood
lymphocytes failed to stain for sheep IgG. Four
hours after the second infusion the cells were again
positive for sheep IgG, with 21% staining strongly
and most of the remainder showing some staining.
On this occasion the strongly staining cells
displayed their sheep antibody in prominent caps,
while extensive patching was evident on many of
the more weakly staining cells. When the surface Ig
was stained directly with fluoresceinated anti-K or
anti-s the same capped and patched distribution
was seen, but some 10% of the cells with tumour
morphology failed to stain at all. Cells from a
sample taken three days later had regained their
original staining characteristics and showed no
trace of sheep antibody.
At no time during the course of study could the
harvested cells which displayed sheep antibody be
lyzed simply by the addition of rabbit complement.
Addition of a high concentration of anti-idiotype
together with the complement gave low but consis-
tent lysis throughout the therapy.
Patient DH This patient received only one
infusion, 2.0g of antibody-containing IgG1 in
500ml saline given over 2h. No untoward reaction
occurred. Prior plasmapheresis was not considered
necessary because no idiotype-positive Ig was
detected in the serum.
Shortly after the infusion lymphocyte count had
fallen to about 40% of the original level, but over
the ensuing three days rose to regain it (Figure 9).
Throughout this period the majority of cells were
recoverable from Ficoll-Triosil gradients. Sheep
IgG was detected by immunofluorescence on all
tumour cells recovered immediately post-infusion,
on 23% of the cells a day later, and on no cells
after a further two days. In the first sample the
predominant antibody distribution was circum-
ferential and speckled, in the second most of the
positive cells displayed capping. Separate staining
for the cells' intrinsic surface Ig reflected these
patterns. In the first sample, and only in this
sample, many of the cells underwent lysis simply
upon the addition of rabbit complement (using a
serum selected for a high level of lytic complement).
No lysis was observed in this sample upon addition
of human complement.
A serum sample taken immediately post-infusion
contained an appreciable concentration of free anti-
idiotype. Thus pre-infusion cells incubated with this
serum at 0°C could subsequently be stained for
sheep IgG in immunofluorescence tests, and could
be lyzed upon incubation with rabbit complement
at 37°C. Serum taken a day later yielded only weak
staining, and failed to invoke lysis by rabbit
complement. In no other patient was free anti-
idiotype thus demonstrable in a post-infusion serum
sample.
Discussion
These early results do not reflect the therapeutic
potential of anti-idiotype - being exceeded in both
published (Miller et al., 1982) and current cases -
but they are presented to highlight two particular
problems encountered in treating neoplasms with
antibody, extracellular antigen and antigenic
modulation. These and other factors permitting
escape of tumour cells from antibody are listed in
Table III.
The basic concept of therapy using anti-idiotype
assumed that CLL and lymphoma cells in general
synthesize Ig solely for insertion into the plasma
membrane (Stevenson & Stevenson, 1975). However
Table Ill Factors militating against the killing of tumour
cells by infused antibody
Inaccessibility of the cells
Sparseness of surface antigen
Modulation of surface antigen
Extracellular antigen
Inadequate or inappropriate recruitment of effectors
Exhaustion of effectors
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it appears now that in most of these tumours both
pathways of Ig synthesis, that for membrane
insertion and that for export (secretion), are active
(Stevenson et al., 1980). The export of Ig per cell is
small, but can yield a significant concentration of
Ig in extracellular fluid when summed over a large
tumour load. This has occurred in patients CW, OJ
and MW. Our experience to date, exemplified by
the four patients in the present study, has been that
whenever export of Ig by tumour cells in vitro can
be demonstrated the patient will exhibit a
significant level of idiotypic Ig in his plasma. This
is of some utility, as it is possible to carry out the
synthetic studies well before anti-idiotype is
available to assay for the presence of idiotype in
plasma. The presence of extracellular antigen in the
amounts encountered in the idiotype system is
probably unusual among cell surface antigens in
general. It is certainly not unique: Nadler et al.
(1980) encountered a problem of similar magnitude
in the therapeutic use of a monoclonal antibody
(Ab89) reactive with about 10% of B-lymphocytic
neoplasms.
An infusion of antibody in the face of circulating
idiotypic Ig will result in consumption of antibody,
consumption of effectors such as complement and
phagocytic capacity, and possible toxic effects due
to the generation of immune complexes. No serious
consequence of complex formation, and in
particular no significant renal damage, has been
observed to follow the use of anti-idiotype or the
Ab89 antibody (Nadler et al., 1980). However the
complexes probably contribute to minor immediate
toxicity such as pyrexia and bronchoconstriction
(Hamblin et al., 1980). These effects appear to be
minimized by giving the antibody infusion slowly.
Extracellular idiotype can be reduced in amount
by plasmapheresis or chemotherapeutic reduction of
tumour. In the latter case sufficient time should be
allowed for clearance of any Ig released from
damaged cells. The need to swamp residual extra-
cellular antigen with antibody must be taken into
account in planning: it represents a strong
argument in favour of monoclonal anti-idiotype
(Miller et al., 1982), which in principle at least is
available in indefinitely large amount.
Appreciable killing of CW and probably of OJ
cells was observed without reducing the extra-
cellular idiotype to zero. There is a suggestion here
that the effective antibody association constant
might be greater for antigen on the cell surface than
for antigen in the fluid phase. Uncertainties arise
because there may have been transient local
elimination of extracellular idiotype, and because
small immune complexes might show persistent
activity in assays for idiotype.
Antigenic modulation, originally defined as
antibody-induced resistance to the cytotoxic action
of antibody plus complement (Boyse & Old, 1969),
is associated with redistribution of antigen-antibody
complexes on the cell surface (Stackpole et al.,
1974). It does not require complete clearance of the
complexes from the surface, and in the case of
surface Ig can occur with a rapidity sufficient to
provide some protection for cells confronted simul-
taneously by antibody and complement (Gordon &
Stevenson, 1981). The poor performance of human
complement in killing OJ, DH and MW cells in
vitro was probably due largely to modulation
competing with the complement cascade when
antibody-coated cells were warmed to 37°C in the
presence of serum.
The complete modulation of CW cells at the
nadir after antibody infusion suggests that it was
the modulation which permitted cellular survival in
vivo. The better survival afforded in a guinea pig
leukaemia by univalent anti-idiotype, which avoids
modulation (Glennie & Stevenson, 1982) is also
consistent with this interpretation. It should be
noted that modulation can protect against cellular
effectors (Griffin et al., 1976; Stevenson et al., 1982)
as well as against complement. The occurrence of
modulation in human tumour cells under attack by
a variety of monoclonal antibodies has recently
been reviewed by Ritz & Schlossman (1982).
Observations in this paper refer only to the
killing of neoplastic cells in the vascular compart-
ment. No diminution in size of tumour masses was
observed, although the number of dead cells seen in
the blood of CW soon after antibody infusion
(Figure 6), which exceeds the total white cell count
before the infusion, suggests that some cells in a
readily accessible tissue compartment may have
been killed and then released into the blood.
Antibody-coated cells in the vascular compartment
are exposed to high concentrations of complement
components so it is likely that complement is here a
major mechanism for cellular destruction. In
contrast the usefulness of complement against cells
in tissues is problematical, and some immunothera-
peutic observations in animals and man suggest
'that it does not have an important role (Lanier et
al., 1980; Miller et al., 1982). Although K cells, NK
cells and macrophages are known to attack
antibody-coated cells in vitro (e.g. Ojo & Wigzell,
1978; Kumagai et al., 1981; Lawson & Stevenson,
1983) it is difficult to extrapolate these findings to
environments in vivo. Lacking such precise
knowledge makes it difficult to select antibody
isotypes, and we have accordingly included in Table
III the heading inadequate or inappropriate
recruitment of effectors.
Transient exhaustion of complement or cellular
effectors, in the killing of cells and clearing of556 J. GORDON et al.
complexes and debris, is a possible consequence of
large antibody infusions. Apparently an exhaustion
of phagocytic capacity led to a delay in clearing
dead cells from the blood of CW. A similar brief
appearance of circulating dead cells after antibody
treatment was reported by Nadler et al. (1980).
It has long been appreciated that insufficient
antigen density on a target cell can lead to a failure
of antibody plus complement to lyse the cell (e.g.
Linscott, 1970; Lesley et al., 1974; Gordon et al.,
1982). Cell-mediated lysis (Lesley et al., 1974) or
cytostasis (Lawson & Stevenson, 1983) does not
appear so susceptible. Results in the present study,
particularly the better complement killing observed
for CW cells, are consistent with surface antigen
density having a significant role in determining the
susceptibility of cells to killing by antibody in the
vascular compartment.
There are indications that many patients treated
for tumour with antibody will eventually exhibit a
troublesome immune response to the foreign Ig
(Miller & Levy, 1981; Miller et al., 1981; Ritz et al.,
1981; Linch et al., 1983). This has not yet been
observed in any of our patients, nor apparently in
other patients with B-lymphocytic neoplasms. This
presumably is due chiefly to the extent of disease-
associated immunosuppression present. Other
factors tending to minimize the danger of an
immune response would include the meticulous
removal of aggregates from the infused Ig and
concomitant treatment with cytotoxic drugs.
In surveying the factors tending to limit the
efficacy of antibody therapy we do not see any
single item looming as completely insoluble. There
appears to be no good reason why antibody
therapy should not be developed as a significant
and safe means ofdisadvantaging neoplastic cells.
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Council, the Cancer Research Campaign, and Tenovus.
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